Genflow Biosciences Reports Strong Safety Profile After Completing Dosing of AAV SIRT6 Gene Therapy in Canine Clinical Trial

LONDON, UK / ACCESS Newswire / December 16, 2025 — Genflow Biosciences Plc, a biotechnology company focused on extending healthspan through advanced gene therapies, today announced that all dogs enrolled in its ongoing clinical trial have successfully received the full administration of the Company’s investigational AAV SIRT6-based gene therapy.

The Company reported a critical milestone in the safety evaluation of the AAV therapy, noting that no adverse events were reported during the dosing phase of the study. No serious, moderate, or minor side effects were observed, demonstrating a strong safety and tolerability profile for the AAV delivery system.

Efficacy Readouts Scheduled

As the study is being conducted as a blinded clinical trial, efficacy outcomes cannot yet be assessed. Monitoring of the enrolled dogs, which received the AAV dose, will continue for a total duration of 180 days.

• Initial Efficacy Readout: Genflow anticipates a first efficacy read in mid-to-late January 2026. This assessment will include blood analyses and muscle biopsies to evaluate potential therapeutic benefits related to sarcopenia, overall healthspan, and lifespan-associated biomarkers stemming from the AAV delivery of the gene.

• Long-Term Results: A second efficacy assessment is planned at the six-month timepoint, with results expected in June-July 2026, to evaluate the durability and longer-term effects of the AAV gene therapy.

“The absence of any adverse events is highly encouraging and reinforces the strong safety profile of our AAV approach,” commented Dr. Eric Leire, CEO of Genflow. “We look forward to sharing initial efficacy data in the coming months as the study progresses.”

Following the analysis of the efficacy data, Genflow intends to resume discussions with several animal health companies, including those currently engaged under confidentiality agreements, to explore potential early-stage licensing opportunities for the AAV technology.